



Balance Sheet As On 2024.MAR

	Selection	Description
Time	2024.MAR	2023-24 MAR
Category	Actual	Actual
Legal Entity	7830	Taro Pharma Corporation, Inc.
<b>Double click to change comparison year</b>		
<b>2022.AUG</b>		
Description	2023-24 MAR	2022-23 AUG
<b>ASSETS</b>		
110XXXXXX - Cash and cash equivalents	1.00	
114XXXXXX - ST Bank Deposits		
115XXXXXX - Restricted Short Term Bank Deposits		
116XXXXXX - Marketable Securities		
117XXXXXX - ST BANK DEPOSITS		
120XXXXXX - IC Trade receivables		
125XXXXXX - IC Other Receivable		
128XXXXXX - IC Loan Receivable		
140XXXXXX - Trade:Open Accounts+Ch.Rec.		
150XXXXXX - Accounts Receivable-Other		
155XXXXXX - Corporate tax receivable		
160XXXXXX - Inventories		
165XXXXXX - Assets HFS-Cost		
166XXXXXX - Asset HFS-Acc Dep		
170XXXXXX - Deferred Tax Ast -Short Term		
173XXXXXX - Total assets attributed to discontinued operations		
<b>AST100 - Current Assets</b>	<b>1.00</b>	
195XXXXXX - Long term investments		
196XXXXXX - Long Term Bank Deposits		
197XXXXXX - Long Term Marketable Securities		
<b>AST110 - Long Term Investments</b>		
187XXXXXX - ROU Asset -Cost		
189XXXXXX - ROU Asset -Accum.Dep		
<b>AST120 - ROU Aseets</b>		
180XXXXXX - Fixed Asset-Cost		
185XXXXXX - Fixed Asset -Accum. Dep		
<b>AST130 - PPE, NET</b>		
200XXXXXX - Intangible Asset-cost		
205XXXXXX - Intangible Asset -Accum.Dep		
<b>AST140 - Other Asset and Deferred Charges</b>		
190XXXXXX - Goodwill&deffe.fin.cha.		
<b>AST150 - Goodwill</b>		
210XXXXXX - Deffered Tax Asset-Long Term		
<b>AST160 - Deferred Income Tax</b>		
175XXXXXX - Subsidiaries		
<b>AST170 - Investment in SUBS</b>		
<b>ASSETS - TOTAL Asset</b>	<b>1.00</b>	
<b>Liabilities and Stockholder's Equity</b>		
300XXXXXX - Short term bank credits		
330XXXXXX - Accounts payable		
340XXXXXX - Current liabilities-Others		
345XXXXXX - Deferred tax liability-Short Term		
350XXXXXX - Taxes Payable		
370XXXXXX - Short term bank credits		
317XXXXXX - IC Other Payables		
310XXXXXX - IC Trade Payables		
315XXXXXX - IC Loan payable		
<b>LEQ100 - CURRENT LIABILITIES:</b>		
400XXXXXX - Long term liabilities		
410XXXXXX - SWAP/ Forward Contracts		
420XXXXXX - Deferred tax liability-Long Term		
430XXXXXX - Amount Accrued/ Other long term liabilities		
460XXXXXX - Capital Note		
<b>LEQ110 - LONG TERM LIABILITIES:</b>		
LEQ120 - Commitments and Contingent (DO NOT PULL FROM SCHEDULES)		
500XXXXXX - Share Capital	1.00	
505XXXXXX - Treasury stock		
510XXXXXX - Additional paid-in capital		
515XXXXXX - Deferred Stock Compensation		
525XXXXXX - Accumulated other comprehensive loss		
535XXXXXX - For. cur. tra.adjs.taro		
540XXXXXX - Re-measurements of defined benefits plans (IAS-19)		
545XXXXXX - Unrealized income-marketable securities		
548XXXXXX - To be deleted when moving to PRD		
549XXXXXX - Retained earnings		
555100 - MINORITY INTEREST		
<b>LEQ140 - SHAREHOLDERS EQUITY</b>	<b>1.00</b>	
<b>LIABILITY - Total Liabilities and Stockholder's equity</b>	<b>1.00</b>	
<b>Balance Sheet Validation</b>	<b>-</b>	<b>-</b>



Statement Of Income For Period Ending 2024.MAR

	Selection	Description
Time	2024.MAR	2023-24 MAR
Category	Actual	Actual
Legal Entity	7830	Taro Pharma Corporation, Inc.
		<a href="#">Double click to change comparison year</a>
		2022.AUG
Description	2023-24 MAR	2022-23 AUG
700XXXXXX - Sales(3rd Party)		
710XXXXXX - IC Sale of RM/FG/TP (sales)		
<b>SAL100 - Sales</b>		
800XXXXXX - Cost of Sales		
801XXXXXX - IC Cost fo Sales		
802XXXXXX - COGS Impairment Expenses		
<b>COS100 - Total cost of sales</b>		
<b>GP - Gross Profit</b>		
855XXXXXX - IC Portfolio management fees (R&D)		
<b>850XXXXXX - Total Research and Development Expenses</b>		
860XXXXXX - Selling Expenses		
862XXXXXX - G&A Impairment Costs		
865XXXXXX - Administrative Expenses		
867XXXXXX - Settlements and loss contingencies		
<b>OPE100 - Total operating expenses</b>		
<b>GPOPE - Operating Income/(Loss)</b>		
875XXXXXX - Financial Expense (Income), net		
876XXXXXX - IC Interest, net		
<b>FIN100 - Total Finance Exp/ (Income), net</b>		
880XXXXXX - Other Income		
852XXXXXX - IC Marketing Support, website and development costs, net		
881XXXXXX - IC Royalties, net		
<b>OIC100 - Total Other Income/ (Expense), net</b>		
<b>PBT - Profit/ (Loss) before taxes on income</b>		
885XXXXXX - Taxes on Income		
<b>PAT - Profit/ (Loss) before Subsidiary</b>		
888100 - Discontinued operation		
890100 - P&L Subsidiaries		
892100 - FX From USA loan to Canada		
894100 - Internal profit in Inven.		
896100 - Tax effect of internal profit		
897100 - Dividend, net		
898100 - Minority Share in Profits		
<b>PL - Total Profit/ (Loss)</b>		



	Selection	Description
Time	2024.MAR	2023-24 MAR
Category	Actual	Actual
Legal Entity	7830	Taro Pharma Corporation, Inc.

Description	Opening balance.	Addition	Taken over on acquisition	Acquisition of new subsidiary	Disposals or Retirals	Disposal of Subsidiary	TOTAL
500100 - Share Capital		1					1.00
510100 - Options to Associates (FAS 123)							
520100 - Premium on shares							
530100 - Capital Contribution (Premium)							
515100 - Deferred Stock Compensation							
525100 - Unrealized (income)/ loss- Hedge Accounting							
535100 - For. cur. tra.adjs.taro(TB)							
535101 - IC Exchange Difference							
535102 - For. cur. tra.adjs.taro(His-calculated)							
535103 - Translation Difference							
535104 - PL Exhange Difference							
535105 - QTD Impact							
540100 - Re-measurements of defined benefits plans (IAS-19)							
545100 - Unrealized income-marketable securities							
545200 - DTA on OCI related to Marketable Securities							
505100 - Treasury stock							
549100 - Retained Earnings (equity reclass.)							
550100 - Accumulated earnings							
560100 - Net Income							
548100 - Dividend							
555100 - MINORITY INTEREST							